178269-54-0

Basic information

• Product Name: 4-methyl-2-propylpent-4-enoic acid
• CAS NO: 178269-54-0
• Molecular Formula: C₉H₁₆O₂
• Molecular Weight: 156.2221
• Mol File: 178269-54-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 246.9°C at 760 mmHg
• Flash Point: 144.2°C
• Density: 0.935g/cm³
• Vapor Pressure: 0.00853mmHg at 25°C
• Refractive Index: 1.449
• CAS DataBase Reference: 4-methyl-2-propylpent-4-enoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-2-propylpent-4-enoic acid(178269-54-0)
• EPA Substance Registry System: 4-methyl-2-propylpent-4-enoic acid(178269-54-0)

Safety Data

• Hazardous Substances Data: 178269-54-0(Hazardous Substances Data)

Upstream product

• 854833-31-1 (2-methyl-allyl)-propyl-malonic acid diethyl ester 
• 2163-48-6 diethyl propylmalonate 
• 563-47-3 3-Chloro-2-methylpropene 

Relevant articles and documents

Enantioselective synthesis of valproic acid analogues

This invention employs camphorsultam as a chiral recoverable auxiliary to provide a new method for manufacturing valproic acid and valproic acid amides that facilitates the enantioselective or diasteroselective production of valproic acid analogs on a larger scale.

Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid.

Twelve racemic analogues of the antiepileptic drug valproic acid (VPA) were tested and compared with VPA for anticonvulsant activity by the subcutaneous pentylenetetrazol (PTZ) seizure threshold test and for neurotoxicity by the rotorod test. Four compounds produced maximal anticonvulsant activity (100% protection) in equimolar doses (1.5 mmol/kg) to VPA and two compounds showed a similar effect with lower doses (1.0 mmol/kg). Four compounds produced lower activity (38-80% protection), and two compounds showed no anticonvulsant activity at the dose used (1.5 mmol/kg). Two of the 12 compounds, (+/-)-2-n-propyl-4-hexynoic acid (11) and (+/-)-4-methyl-2-n-propyl-4-pentenoic acid (12), showed no sedation at doses that produced the maximum anticonvulsant effect. For the first time we succeeded to develop two compounds with higher protective index and safety ratios than VPA. Compound 11 had a longer duration of action and higher protective index but a lower safety ratio than 12. Comparisons of the anticonvulsant and minimal neurotoxic effects of these compounds with their calculated lipophilicity (C log P) revealed that compounds with the desired high anticonvulsant activity and minimal neurotoxicity showed C log P values between 1.84 and 2.64 and had nine carbon atoms (in contrast to eight carbon atoms for VPA).